{
    "clinical_study": {
        "@rank": "3279", 
        "arm_group": {
            "arm_group_label": "VM202", 
            "arm_group_type": "Experimental", 
            "description": "Total dose of 64 mg of VM202 It will be administered over the course of four visits: Day 0, Day 7, Day 14, and Day 21.  As in all previous VM202 studies, final dose of VM202 for each target muscle group is divided and administered 2 weeks apart."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and tolerability of intramuscular\n      injections of VM202 at different injection sites in people with amyotrophic lateral\n      sclerosis."
        }, 
        "brief_title": "Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Amyotrophic Lateral Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Amyotrophic Lateral Sclerosis", 
                "Sclerosis", 
                "Motor Neuron Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 21 years, but < or =  75 years\n\n          -  Subjects diagnosed with:\n\n               -  clinically definite ALS,\n\n               -  clinically probable ALS, or\n\n               -  clinically probable-laboratory supported ALS as specified in the revised El\n                  Escorial / Airlie House diagnostic criteria\n\n          -  Onset of ALS < 2 years at Screening\n\n          -  Forced Vital Capacity (FVC) \u2265 60% of predicted\n\n          -  Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) \u2265 30\n\n          -  Not taking riluzole, or on a stable dose for at least thirty days prior to Screening\n             (defined as no noted toxicities)\n\n          -  Able and willing to give informed consent\n\n          -  If female of childbearing potential, negative urine pregnancy test at Screening and\n             using acceptable method of birth control during the study.\n\n        Exclusion Criteria:\n\n          -  Neurological symptom(s) due to vitamin B12 deficiency\n\n          -  Requires tracheotomy ventilation or noninvasive ventilation > 16 hours / day\n\n          -  Comorbidities such as Parkinson's disease, schizophrenia, renal failure, or any other\n             severe complication that, in the Investigator's opinion, will compromise the safety\n             of the patient or confound interpretation of the data collected in this study\n\n          -  Other neuromuscular disease\n\n          -  Inflammatory disorder of the blood vessels (inflammatory angiopathy, such as\n             Buerger's disease)\n\n          -  Active infection\n\n          -  Chronic inflammatory disease (e.g., Crohn's disease, rheumatoid arthritis)\n\n          -  Positive HIV or HTLV at Screening\n\n          -  Active Hepatitis B or C as determined by Hepatitis B core antibody (HBcAb), antibody\n             to Hepatitis B surface antigen (IgG and IgM; HBsAb), Hepatitis B surface antigen\n             (HBsAg) and Hepatitis C antibodies (Anti-HCV) at Screening\n\n          -  Subjects with known immunosuppression or currently receiving immunosuppressive drugs,\n             chemotherapy or radiation therapy\n\n          -  Stroke or myocardial infarction within last 3 months\n\n          -  Patients with a recent history (< 5 years) of malignant neoplasm except basal cell\n             carcinoma or squamous cell carcinoma of the skin (if excised and no evidence of\n             recurrence);\n\n          -  Subjects requiring > 81 mg daily of acetylsalicylic acid; subjects may be enrolled if\n             willing/able to switch to \u2264 81 mg daily of acetylsalicylic acid or to another\n             medication\n\n          -  Subjects requiring regular COX-2 inhibitor drug(s) or non-specific COX-1/COX-2\n             inhibiting drugs, or high dose steroids (excepting inhaled steroids); subjects may be\n             enrolled if willing/able to undergo medication wash-out prior to the first dosing and\n             to refrain from taking these drugs for the duration of the study\n\n          -  Have used an investigational drug within 30 days of Screening\n\n          -  Pregnant or currently lactating\n\n          -  Major psychiatric disorder in past 6 months\n\n          -  Known drug or alcohol dependence or any other factors which will interfere with the\n             study conduct or interpretation of the results or who in the opinion of the\n             Investigator are not suitable to participate."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02039401", 
            "org_study_id": "VMALS-001 / B"
        }, 
        "intervention": {
            "arm_group_label": "VM202", 
            "intervention_name": "VM202", 
            "intervention_type": "Genetic"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "ALS", 
            "Lou Gehrig's disease", 
            "neurodegenerative disease"
        ], 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "contact": {
                "email": "ALSResearch@nmff.org", 
                "last_name": "Pat Casey"
            }, 
            "contact_backup": {
                "email": "ALSResearch@nmff.org", 
                "last_name": "Jennifer Armstrong"
            }, 
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60611"
                }, 
                "name": "Northwestern University"
            }, 
            "investigator": [
                {
                    "last_name": "Robert Sufit, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Senda Driss, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I/II, Open Label Study to Assess the Safety and Tolerability of VM202 in Subjects With Amyotrophic Lateral Sclerosis", 
        "other_outcome": [
            {
                "description": "There are twelve questions, some asking about daily activities and how much help a patient needs with them, and some about specific symptoms.", 
                "measure": "The revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R)", 
                "safety_issue": "No", 
                "time_frame": "Screening, on Day 0 before the treatment (injection), on Day 30, Day 60, Day 90, at 6 months and 9 months"
            }, 
            {
                "description": "Measurements will be taken bilaterally:\nMid-arm: at the midpoint of a vertical line that joins the acromion process to the olecranon process\nMid forearm: at the proximal one third point of a vertical line that joins the medial epicondyle to the styloid process of the ulna\nMid-thigh: midpoint of a vertical line that joins the anterior superior iliac spine to the superior edge of the patella\nMid-leg: at the proximal one third point of a vertical line that joins the fibular head to the lateral malleolus", 
                "measure": "Muscle Circumference", 
                "safety_issue": "No", 
                "time_frame": "Day 60, Day 90, at 6 months, and 9 months"
            }, 
            {
                "description": "pulmonary function test that quantifies the volume of air that can forcibly be blown out after full inspiration.  It correlates with survival in ALS", 
                "measure": "Forced vital capacity", 
                "safety_issue": "No", 
                "time_frame": "Screening, on Day 0 before the treatment (injection), on Day 30, Day 60, Day 90, at 6 months and 9 month"
            }, 
            {
                "description": "determined by using the Medical research Council (MRC) scale", 
                "measure": "muscle strength", 
                "safety_issue": "No", 
                "time_frame": "Day 30, Day 60, Day 90, at 6 months and 9 months"
            }
        ], 
        "overall_official": {
            "affiliation": "Northwestern University Stem Cell Institute", 
            "last_name": "John A Kessler, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adverse events (including serious adverse events, and adverse events leading to treatment discontinuation) throughout the 9 months follow-up will be described according to severity and to their relationship with the study drug and injection procedure. Descriptive statistics will be used to characterize safety parameters.", 
            "measure": "Number of subjects with serious and non serious adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Throughout the nine month follow up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02039401"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Hepatocyte Growth Factor (HGF) serum levels", 
                "safety_issue": "No", 
                "time_frame": "immediately pre-treatment on Day 0, immediately pre-treatment on Day 7, immediately pre-treatment on Day 14, immediately pre-treatment on Day 21, on Day 30, Day 60 and Day 90"
            }, 
            {
                "measure": "Copies of VM202 in whole blood", 
                "safety_issue": "No", 
                "time_frame": "Day 0, 7, 14, 21 (pre and post last injection), and  Day 30, 60 and 90"
            }
        ], 
        "source": "ViroMed Co., Ltd. dba VM BioPharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ViroMed Co., Ltd. dba VM BioPharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}